Streetbeat News

MLTX

MoonLake Immunotherapeutics

https://www.moonlaketx.com

Industry

Biotechnology

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

Open

51.98

Mkt cap

3.1B

Volume

401K

High

51.98

P/E Ratio

-38.45

52-wk high

64.98

Low

48.30

Div yield

N/A

52-wk low

37.55

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on MoonLake (NASDAQ:MLTX) and maintained a $100 price target.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 11:27 am

Moonlake Immunotherapeutics has entered into a three-year technology partnership with Komodo Health to enhance research on inflammatory skin and joint conditions. This collaboration aims to leverage Komodo Health's technological capabilities to advance Moonlake Immunotherapeutics' research efforts in these areas.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 11:06 am

Needham analyst Serge Belanger has reiterated a Buy rating on MoonLake (NASDAQ:MLTX) and maintained a $66 price target. This reaffirms Needham's positive outlook on MLTX's stock.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 9:57 am

Goldman Sachs analyst Richard Law initiates coverage on MoonLake (NASDAQ:MLTX) with a Neutral rating and sets a price target of $62.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 11:05 am

MoonLake Immunotherapeutics' shares experienced a significant increase as traders shared comments from Betaville, suggesting potential positive developments for the company.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 4:02 pm

Wedbush analyst Andreas Argyrides reiterates an Outperform rating on MoonLake (NASDAQ:MLTX) and maintains a $92 price target.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 1:27 pm

MoonLake Immunotherapeutics (NASDAQ:MLTX) reported significant improvements in psoriatic arthritis outcomes from the ARGO trial of Nanobody sonelokimab, surpassing results of AbbVie Inc's (NYSE:ABBV) Humira. MLTX plans to start Phase 3 trials in 2024, with shares up 3%.

Portfolio Pulse from Vandana Singh

March 11, 2024 | 1:56 pm

Wedbush analyst Andreas Argyrides has reiterated an Outperform rating on MoonLake (NASDAQ:MLTX) and maintained a $92 price target.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 12:48 pm

MoonLake Immunotherapeutics' stock is trading higher following the announcement of positive 24-week data from the ARGO trial in psoriatic arthritis, along with other research and development updates.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:50 am

HC Wainwright & Co. analyst Raghuram Selvaraju maintains a Buy rating on MoonLake (NASDAQ:MLTX) and raises the price target from $75 to $100.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:17 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.